US2003144241A1PendingUtilityA1

Antisense modulation of Smad6 expression

Priority: Oct 4, 2000Filed: Dec 20, 2002Published: Jul 31, 2003
Est. expiryOct 4, 2020(expired)· nominal 20-yr term from priority
C12N 2310/346C12N 2310/315C12N 2310/341Y02P20/582C12N 2310/321C12N 2310/3341A61K 48/00C12N 15/113A61K 38/00
57
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Antisense compounds, compositions and methods are provided for modulating the expression of Smad6. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Smad6. Methods of using these compounds for modulation of Smad6 expression and for treatment of diseases associated with expression of Smad6 are provided.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding Smad6, wherein said compound specifically hybridizes with and inhibits the expression of Smad6.  
     
     
         2 . The compound of  claim 1  which is an antisense oligonucleotide.  
     
     
         3 . The compound of  claim 2  wherein the antisense oligonucleotide has a sequence comprising SEQ ID NO: 12, 13, 19, 26, 27, 29, 40, 11, 14, 17, 21, 28, 41 or 45.  
     
     
         4 . The compound of  claim 2  wherein the antisense oligonucleotide has a sequence comprising SEQ ID NO:26, 29 or 40.  
     
     
         5 . The compound of  claim 2  wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.  
     
     
         6 . The compound of  claim 5  wherein the modified internucleoside linkage is a phosphorothioate linkage.  
     
     
         7 . The compound of  claim 2  wherein the antisense oligonucleotide comprises at least one modified sugar moiety.  
     
     
         8 . The compound of  claim 7  wherein the modified sugar moiety is a 2′-O-methoxyethyl sugar moiety.  
     
     
         9 . The compound of  claim 2  wherein the antisense oligonucleotide comprises at least one modified nucleobase.  
     
     
         10 . The compound of  claim 9  wherein the modified nucleobase is a 5-methylcytosine.  
     
     
         11 . The compound of  claim 2  wherein the antisense oligonucleotide is a chimeric oligonucleotide.  
     
     
         12 . A compound 8 to 50 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of an active site on a nucleic acid molecule encoding Smad6.  
     
     
         13 . A composition comprising the compound of  claim 1  and a pharmaceutically acceptable carrier or diluent.  
     
     
         14 . The composition of  claim 13  further comprising a colloidal dispersion system.  
     
     
         15 . The composition of  claim 13  wherein the compound is an antisense oligonucleotide.  
     
     
         16 . A method of inhibiting the expression of Smad6 in cells or tissues comprising contacting said cells or tissues with the compound of  claim 1  so that expression of Smad6 is inhibited.  
     
     
         17 . A method of treating an animal having a disease or condition associated with Smad6 comprising administering to said animal a therapeutically or prophylactically effective amount of the compound of  claim 1  so that expression of Smad6 is inhibited.  
     
     
         18 . The method of  claim 17  wherein the disease or condition is a cardiovascular disease or cancer.

Join the waitlist — get patent alerts

Track US2003144241A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.